Controlling CRS-related coagulopathy improves the safety of CAR T-cell therapy for MM

ICARIA results: Treating RRMM patients with isatuximab, pomalidomide and low-dose dexamethasone

HORIZON update: Using melflufen to treat RRMM patients refractory to daratumumab and/or pomalidomide

PET after 2 cycles of ABVD in patients with early-stage favourable Hodgkin lymphoma

Safety and efficacy of escalating doses of Hu5F9-G4 with rituximab in patients with R/R DLBCL and indolent lymphoma

Combination of pegcrisantaspase and venetoclax in acute myeloid leukaemia

CLL12 trial: Ibrutinib in previously untreated, asymptomatic early-stage CLL

Chemoimmunotherapy or BTK inhibition for patients with CLL

MOR208 plus lenalidomide in r-r diffuse large B-cell lymphoma

Blinatumomab for relapsed/refractory Burkitt's lymphoma

Using bioinformatics and genomics to treat AML

The changing landscape of AML